We are live on ! Find out more
EWTX icon

Edgewise Therapeutics

178 hedge funds and large institutions have $1.56B invested in Edgewise Therapeutics in 2025 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 88 increasing their positions, 39 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

126% more repeat investments, than reductions

Existing positions increased: 88 | Existing positions reduced: 39

2.23% more ownership

Funds ownership: 110.64%112.87% (+2.2%)

7% less funds holding

Funds holding: 192178 (-14)

20% less funds holding in top 10

Funds holding in top 10: 108 (-2)

27% less first-time investments, than exits

New positions opened: 30 | Existing positions closed: 41

33% less call options, than puts

Call options by funds: $775K | Put options by funds: $1.15M

33% less capital invested

Capital invested by funds: $2.32B → $1.56B (-$764M)

Holders
178
Holders Change
-14
Holders Change %
-7.29%
% of All Funds
2.34%
Holding in Top 10
8
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-20%
% of All Funds
0.11%
New
30
Increased
88
Reduced
39
Closed
41
Calls
$775K
Puts
$1.15M
Net Calls
-$374K
Net Calls Change
-$29.3M
Name Holding Trade Value Shares
Change
Change in
Stake
Barclays
51
Barclays
United Kingdom
$3.69M +$2.49M +172,688 +159%
Bank of America
52
Bank of America
North Carolina
$3.34M -$6.36M -440,997 -63%
KCM
53
Kynam Capital Management
New Jersey
$3.33M +$3.66M +253,979 New
KCM
54
Kennedy Capital Management
Missouri
$3.31M +$401K +27,824 +12%
DCM
55
DAFNA Capital Management
California
$3.12M +$793K +55,000 +30%
CS
56
Candriam SCA
Luxembourg
$2.94M -$26K -1,806 -0.8%
Bank of New York Mellon
57
Bank of New York Mellon
New York
$2.79M +$30.6K +2,123 +1%
UBS AM
58
UBS AM
Illinois
$2.51M -$1.17M -81,251 -30%
UBS Group
59
UBS Group
Switzerland
$2.24M -$1.05M -72,914 -30%
SSA
60
Schonfeld Strategic Advisors
New York
$2.19M -$1.61M -111,633 -40%
Neuberger Berman Group
61
Neuberger Berman Group
New York
$2.17M +$914K +63,354 +62%
Schroder Investment Management Group
62
Schroder Investment Management Group
United Kingdom
$1.98M +$1.04M +71,911 +91%
Deutsche Bank
63
Deutsche Bank
Germany
$1.93M -$3.3M -228,535 -61%
Universal-Beteiligungs- und Servicegesellschaft
64
Universal-Beteiligungs- und Servicegesellschaft
Germany
$1.73M +$617K +42,753 +48%
EAM
65
Exome Asset Management
New York
$1.63M +$765K +53,032 +74%
JF
66
Jump Financial
Illinois
$1.6M +$1.76M +121,705 New
DekaBank Deutsche Girozentrale
67
DekaBank Deutsche Girozentrale
Germany
$1.56M
Susquehanna International Group
68
Susquehanna International Group
Pennsylvania
$1.51M -$885K -61,396 -35%
CCIA
69
Campbell & Co Investment Adviser
Maryland
$1.5M +$1.65M +114,181 New
Wellington Management Group
70
Wellington Management Group
Massachusetts
$1.48M -$10.6K -733 -0.6%
RhumbLine Advisers
71
RhumbLine Advisers
Massachusetts
$1.47M +$52.6K +3,646 +3%
QPW
72
Quantum Private Wealth
Florida
$1.32M +$145K +10,050 +11%
MAP
73
Moody Aldrich Partners
Massachusetts
$1.31M -$1.19M -82,247 -45%
New York State Common Retirement Fund
74
New York State Common Retirement Fund
New York
$1.23M +$322K +22,358 +31%
Swiss National Bank
75
Swiss National Bank
Switzerland
$1.18M +$107K +7,400 +9%

EWTX Hedge Fund Activity: Q2 2025 in Review

178 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Edgewise Therapeutics (EWTX) for Q2 2025, worth a combined $1.56B — down 33% from $2.32B a quarter earlier.

Sellers outnumbered buyers: 41 funds closed out of EWTX and 30 opened new positions — a net loss of 11 holders — while 39 trimmed existing stakes and 88 added.

The largest buyer was Braidwell, adding an estimated $39.7M. The largest seller was Deep Track Capital, exiting entirely with an estimated $30.8M sold.

  • 178 institutional investors held Edgewise Therapeutics (EWTX) as of Q2 2025, down from 192 in Q1 2025.
  • Funds reported $1.56B of Edgewise Therapeutics stock for Q2 2025, down 33% quarter-over-quarter.
  • 30 funds opened new Edgewise Therapeutics positions in Q2 2025 and 41 closed out, a net change of -11 holders.
  • The largest Edgewise Therapeutics buyer in Q2 2025 was Braidwell, an estimated $39.7M added.
  • The largest Edgewise Therapeutics seller in Q2 2025 was Deep Track Capital, an estimated $30.8M sold.

Based on aggregated 13F filings for Q2 2025.